UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

Drugs (New York, N.Y.), 2018-03, Vol.78 (4), p.463-478

2018

Volltextzugriff (PDF)

Safety and efficacy of biosimilars in oncology

The lancet oncology, 2016-11, Vol.17 (11), p.e502-e509

2016

Volltextzugriff (PDF)

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Blood, 2016-06, Vol.127 (26), p.3360-3368

2016

Volltextzugriff (PDF)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood, 2021-07, Vol.137 (26), p.3616-3628

2021

Volltextzugriff (PDF)

Improved differential diagnosis of intracardiac and extracardiac shunts using acoustic intensity mapping of saline contrast studies

European heart journal cardiovascular imaging, 2020-03, Vol.21 (3), p.307-317

2020

Volltextzugriff (PDF)

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Blood, 2012-05, Vol.119 (19), p.4375-4382

2012

Volltextzugriff (PDF)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

British journal of haematology, 2019-05, Vol.185 (3), p.492-502

2019

Volltextzugriff (PDF)

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17 (9), p.575-583.e2

2017

Volltextzugriff (PDF)

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

American journal of hematology, 2018-10, Vol.93 (10), p.1199-1206

2018

Volltextzugriff (PDF)

Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study

Future oncology (London, England), 2022-04, Vol.18 (12), p.1499-1510

2022

Volltextzugriff (PDF)

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2484-2492

2016

Volltextzugriff (PDF)

Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites

Journal of psychiatric research, 2021-05, Vol.137, p.667-672

2021

Volltextzugriff (PDF)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

Cancer, 2020-10, Vol.126 (19), p.4332-4340

2020

Volltextzugriff (PDF)

Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?

Future oncology (London, England), 2024-03, Vol.20 (9), p.481-491

2024

Volltextzugriff (PDF)

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Supportive care in cancer, 2022-10, Vol.30 (10), p.7913-7922

2022

Volltextzugriff (PDF)

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Leukemia & lymphoma, 2022-10, Vol.63 (10), p.2383-2392

2022

Volltextzugriff (PDF)

Demystifying biosimilars: development, regulation and clinical use

Future oncology (London, England), 2019-03, Vol.15 (7), p.777-790

2019

Volltextzugriff (PDF)

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.147-147, Article 147

2023

Volltextzugriff (PDF)

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Annals of hematology, 2018-12, Vol.97 (12), p.2425-2436

2018

Volltextzugriff (PDF)

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

British journal of haematology, 2019-12, Vol.187 (5), p.602-614

2019

Volltextzugriff (PDF)

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

British journal of haematology, 2021-04, Vol.193 (1), p.93-100

2021

Volltextzugriff (PDF)

Recognition of early mortality in multiple myeloma by a prediction matrix

American journal of hematology, 2017-09, Vol.92 (9), p.915-923

2017

Volltextzugriff (PDF)

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Future oncology (London, England), 2024-01, Vol.20 (3), p.131-143

2024

Volltextzugriff (PDF)

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Drugs (New York, N.Y.), 2018-06, Vol.78 (8), p.853-855

2018

Volltextzugriff (PDF)

1 – 25 von 407

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(373)
Mit Volltextzugriff
(328)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(406)
Deutsch
(1)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(171)
Life Sciences & Biomedicine
(162)
Humans
(139)
Male
(94)
Female
(91)
Middle Aged
(70)
Adult
(69)
Aged
(68)
Oncology
(53)
Biological And Medical Sciences
(52)
Medical Sciences
(50)
Hematology
(44)
Aged, 80 And Over
(33)
Multiple Myeloma
(32)
Cardiac & Cardiovascular Systems
(22)
Cardiovascular System & Cardiology
(22)
Treatment Outcome
(22)
Multiple Myeloma - Drug Therapy
(20)
Radiology, Nuclear Medicine & Medical Imaging
(18)
Patients
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

Safety and efficacy of biosimilars in oncology

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Improved differential diagnosis of intracardiac and extracardiac shunts using acoustic intensity mapping of saline contrast studies

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Demystifying biosimilars: development, regulation and clinical use

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

Recognition of early mortality in multiple myeloma by a prediction matrix

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Aktive Filter

Suchergebnisse filtern